Pharmacogenomics: from bedside to clinical practice (Q36465177)

14 August 2017

1 reference

title

Pharmacogenomics: from bedside to clinical practice (English)

1 reference

14 August 2017

1 reference

Sharon Marsh

1

1 reference

14 August 2017

Howard L McLeod

series ordinal

2

1 reference

14 August 2017

publication date

1 April 2006

1 reference

14 August 2017

published in

Human Molecular Genetics

1 reference

14 August 2017

volume

15 Spec No 1

1 reference

14 August 2017

page(s)

R89-93

1 reference

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

21 January 2018

Cancer pharmacogenetics

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

SNP databases and pharmacogenetics: great start, but a long way to go.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Toward genome-wide SNP genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Coding defect and a TATA box mutation at the bilirubin UDP-glucuronosyltransferase gene cause Crigler-Najjar type I disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Long-term treatment with warfarin in Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Vitamin K epoxide reductase: homology, active site and catalytic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Thymidylate synthase pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

High-throughput Genotyping Methods for Pharmacogenomic Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDL087

21 January 2018

Identifiers

DOI

10.1093/HMG/DDL087

1 reference

14 August 2017

1 reference